RAC2 and cancer: In the TCGA cohort, the OS of RAC2 missense-mutant cancers (median, 26.83; interquartile range, 12-48) and RAC2 splicing-mutant cancers (median, 30.61; interquartile range, 9.75-59.81) were not statistically different from those with RAC2 nonmutant disease (median, 23.59; interquartile range, 12.59-44.91).